Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
- Conditions
- LeukemiaAcute Myeloid LeukemiaAML
- Interventions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 175
- Registration Number
- NCT00422591
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- Conditions
- LeukemiaMyelodysplastic Syndrome
- Interventions
- Procedure: Alloreactive NK Infusion
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00402558
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2009-09-16
- Lead Sponsor
- CSL Limited
- Target Recruit Count
- 40
- Registration Number
- NCT00401739
- Locations
- 🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00398983
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2014-08-22
- Target Recruit Count
- 24
- Registration Number
- NCT00387647
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia
- Interventions
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00382590
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 3
- Registration Number
- NCT00363467
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT00358644
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid LeukemiaAML
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2010-02-22
- Lead Sponsor
- Symphony Evolution, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00322673
- Locations
- 🇺🇸
Eddie Hu, Alhambra, California, United States
🇺🇸Ronald Paquette, Los Angeles, California, United States
🇺🇸The Thomas and Dorothy Leavey Cancer Center, Northridge, California, United States
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic SyndromesAcute Myeloid Leukemia
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 16
- Registration Number
- NCT00242515
- Locations
- 🇸🇬
Department of Hematology-Oncology, National University Hospital, Singapore, Singapore